These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25329607)

  • 1. Evaluation of statistical methods for safety signal detection: a simulation study.
    Chen M; Zhu L; Chiruvolu P; Jiang Q
    Pharm Stat; 2015; 14(1):11-9. PubMed ID: 25329607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
    Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study.
    Ahmed I; Thiessard F; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
    Clin Pharmacol Ther; 2010 Oct; 88(4):492-8. PubMed ID: 20811349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.
    Alvarez Y; Hidalgo A; Maignen F; Slattery J
    Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting.
    Ahmed I; Haramburu F; Fourrier-Réglat A; Thiessard F; Kreft-Jais C; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
    Stat Med; 2009 Jun; 28(13):1774-92. PubMed ID: 19360795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
    Xia HA; Ma H; Carlin BP
    J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
    Odani M; Fukimbara S; Sato T
    Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer.
    Matsushita Y; Kuroda Y; Niwa S; Sonehara S; Hamada C; Yoshimura I
    Drug Saf; 2007; 30(8):715-26. PubMed ID: 17696584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of stratification on adverse drug reaction surveillance.
    Hopstadius J; Norén GN; Bate A; Edwards IR
    Drug Saf; 2008; 31(11):1035-48. PubMed ID: 18840023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.
    Huang L; Zalkikar J; Tiwari RC
    J Biopharm Stat; 2013; 23(1):178-200. PubMed ID: 23331230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An MCEM Framework for Drug Safety Signal Detection and Combination from Heterogeneous Real World Evidence.
    Xiao C; Li Y; Baytas IM; Zhou J; Wang F
    Sci Rep; 2018 Jan; 8(1):1806. PubMed ID: 29379048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative methods in pharmacovigilance: focus on signal detection.
    Hauben M; Zhou X
    Drug Saf; 2003; 26(3):159-86. PubMed ID: 12580646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. False discovery rate estimation for frequentist pharmacovigilance signal detection methods.
    Ahmed I; Dalmasso C; Haramburu F; Thiessard F; Broët P; Tubert-Bitter P
    Biometrics; 2010 Mar; 66(1):301-9. PubMed ID: 19432790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 16. Adverse drug effect detection.
    Lian Duan L; Khoshneshin M; Street WN; Liu M
    IEEE J Biomed Health Inform; 2013 Mar; 17(2):305-11. PubMed ID: 24235108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring.
    Stratton KG; Cook AJ; Jackson LA; Nelson JC
    Stat Med; 2015 Mar; 34(7):1117-33. PubMed ID: 25510526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of statistical approaches to postmarketing surveillance.
    Ding Y; Markatou M; Ball R
    Stat Med; 2020 Mar; 39(7):845-874. PubMed ID: 31912927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Logistic Regression Likelihood Ratio Test Analysis for Detecting Signals of Adverse Events in Post-market Safety Surveillance.
    Nam K; Henderson NC; Rohan P; Woo EJ; Russek-Cohen E
    J Biopharm Stat; 2017; 27(6):990-1008. PubMed ID: 28346083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety related drug-labelling changes: findings from two data mining algorithms.
    Hauben M; Reich L
    Drug Saf; 2004; 27(10):735-44. PubMed ID: 15350157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.